JP2018520164A - プロテアソームインヒビターと組み合わせてｍｅｋインヒビターを投与することによりがんを処置する方法 - Google Patents

プロテアソームインヒビターと組み合わせてｍｅｋインヒビターを投与することによりがんを処置する方法 Download PDF

Info

Publication number
JP2018520164A
JP2018520164A JP2018500632A JP2018500632A JP2018520164A JP 2018520164 A JP2018520164 A JP 2018520164A JP 2018500632 A JP2018500632 A JP 2018500632A JP 2018500632 A JP2018500632 A JP 2018500632A JP 2018520164 A JP2018520164 A JP 2018520164A
Authority
JP
Japan
Prior art keywords
cancer
hsf1
mek
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018500632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520164A5 (enExample
Inventor
チェンカイ ダイ，
チェンカイ ダイ，
ジジャン タン，
ジジャン タン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jackson Laboratory
Original Assignee
Jackson Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson Laboratory filed Critical Jackson Laboratory
Publication of JP2018520164A publication Critical patent/JP2018520164A/ja
Publication of JP2018520164A5 publication Critical patent/JP2018520164A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018500632A 2015-07-09 2015-08-11 プロテアソームインヒビターと組み合わせてｍｅｋインヒビターを投与することによりがんを処置する方法 Pending JP2018520164A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190563P 2015-07-09 2015-07-09
US62/190,563 2015-07-09
PCT/US2015/044662 WO2017007495A1 (en) 2015-07-09 2015-08-11 Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor

Publications (2)

Publication Number Publication Date
JP2018520164A true JP2018520164A (ja) 2018-07-26
JP2018520164A5 JP2018520164A5 (enExample) 2018-09-06

Family

ID=57685946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018500632A Pending JP2018520164A (ja) 2015-07-09 2015-08-11 プロテアソームインヒビターと組み合わせてｍｅｋインヒビターを投与することによりがんを処置する方法

Country Status (6)

Country Link
US (1) US20180369203A1 (enExample)
JP (1) JP2018520164A (enExample)
KR (1) KR20180021198A (enExample)
AU (1) AU2015401587A1 (enExample)
CA (1) CA2991777A1 (enExample)
WO (1) WO2017007495A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087840A4 (en) 2020-01-10 2024-01-10 Immuneering Corporation Mek inhibitors and therapeutic uses thereof
US20250099467A1 (en) * 2022-01-25 2025-03-27 Verastem, Inc. Combination therapy for treating abnormal cell growth
CN115120731A (zh) * 2022-07-12 2022-09-30 四川大学华西医院 一种靶向蛋白酶体治疗乳腺癌的药物应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138279A1 (en) * 2013-03-05 2014-09-12 University Of Tennessee Research Foundation Compounds for treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370568B1 (en) * 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138279A1 (en) * 2013-03-05 2014-09-12 University Of Tennessee Research Foundation Compounds for treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF CANCER, vol. 130, JPN6019020376, 2011, pages 967 - 978, ISSN: 0004174094 *
INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 45, JPN6019020377, 2014, pages 929 - 949, ISSN: 0004174095 *

Also Published As

Publication number Publication date
WO2017007495A1 (en) 2017-01-12
KR20180021198A (ko) 2018-02-28
AU2015401587A1 (en) 2018-02-01
US20180369203A1 (en) 2018-12-27
CA2991777A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
Marchi et al. Akt‐mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels and tumor growth
Subramanian et al. HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma
Tang et al. MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1
Lamhamedi-Cherradi et al. An oral formulation of YK-4-279: preclinical efficacy and acquired resistance patterns in Ewing sarcoma
Abboud-Jarrous et al. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL
Al-Mansour et al. Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic
Zhou et al. FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation
Ding et al. Ubiquitination of NOTCH2 by DTX3 suppresses the proliferation and migration of human esophageal carcinoma
Chen et al. Phosphocreatine promotes epigenetic reprogramming to facilitate glioblastoma growth through stabilizing BRD2
Lone et al. Non-POU domain-containing octomer-binding (NONO) protein expression and stability promotes the tumorigenicity and activation of Akt/MAPK/β-catenin pathways in human breast cancer cells
CN105358173A (zh) 靶向癌症治疗的egfr-sglt1相互作用
US20220280590A1 (en) Use of inhibitors of yap and sox2 for the treatment of cancer
Shen et al. AUY922 induces retinal toxicity through attenuating TRPM1
US20240398804A1 (en) Methods of treating cancer having an active wnt/beta-catenin pathway
JP2024096410A (ja) Ｔｆｅｂの活性化方法及びリソソームの生合成方法ならびにそれらのための組成物
KR101640068B1 (ko) Rip3-mlkl 경로 차단제를 포함하는 피부 세포 괴사성 질환 예방 또는 치료용 약학적 조성물
US20180369203A1 (en) Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor
WO2017181943A1 (zh) 含peitc的药物组合物及其在癌症治疗中的应用
WO2017117386A1 (en) Methods of treating cancer using network brakes
US20210363587A1 (en) EPIGENETIC HISTONE REGULATION MEDIATED BY CXorf67
JP2024509887A (ja) Ｅｐ３００分解剤および神経芽細胞腫におけるその使用
US8975293B2 (en) Epigenetic co-repressors of the gamma-globin gene and methods of using same
WO2015073813A2 (en) Compositions and methods for the treatment of diseases involving hippo pathway
US20240082232A1 (en) Compositions and methods for treatment of ovarian and breast cancer
Thoenen Inhibition of ER stress-associated stress granule formation is a novel vulnerability of mutant p53-expressing cancers

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20180406

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20180406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191213